Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 7
Submit an article Journal homepage
201
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Survival outcomes following autologous stem cell transplant with melphalan 140mg/m2 versus 200mg/m2 preparative regimens in patients with multiple myeloma

Nidhi Sharmaa Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USACorrespondence[email protected]
View further author information
,
Evan Bensonb Pre-Medical Program, University of Dayton, Dayton, OH, USAView further author information
,
Qiuhong Zhaoa Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USAView further author information
,
Jordan Nunneleea Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;c The Ohio State University College of Medicine, Columbus, OH, USAView further author information
,
Francesca Cottinia Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USAView further author information
,
Patrick Eldera Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USAView further author information
,
Ashley Roskoa Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USAView further author information
,
Naresh Bummaa Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USAView further author information
,
Abdullah Khana Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USAView further author information
,
Elvira Umyarovaa Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USAView further author information
,
Srinivas Devarakondaa Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USAView further author information
,
Yvonne A. Efeberaa Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;d Department of Internal Medicine, Mayo Clinic, Rochester, MN, USAView further author information
&
Don M. Bensona Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;e Bone Marrow Transplantation & Cellular Therapy, OhioHealth, Columbus, OH, USAView further author information
 show all
Pages 1315-1321 | Received 04 Nov 2022, Accepted 04 May 2023, Published online: 18 May 2023

References

  • McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983;2:822–824.
  • Barlogie B, Hall R, Zander A, et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood. 1986;67(5):1298–1301.
  • Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe français du myélome. N Engl J Med. 1996;335(2):91–97.
  • Abidi MH, Agarwal R, Tageja N, et al. A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function. Biol Blood Marrow Transplant. 2013;19(1):56–61.
  • Bensinger WI, Becker PS, Gooley TA, et al. A randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCT. Bone Marrow Transplant. 2016;51(1):67–71.
  • Hari P, Reece DE, Randhawa J, et al. Final outcomes of escalated melphalan 280 mg/m(2) with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival. Bone Marrow Transplant. 2019;54(2):293–299.
  • Veeraputhiran M, Jain T, Deol A, et al. BEAM conditioning regimen has higher toxicity compared with High-Dose melphalan for salvage autologous hematopoietic stem cell transplantation in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2015;15(9):531–535.
  • Fenk R, Schneider P, Kropff M, et al. High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study. Br J Haematol. 2005;130(4):588–594.
  • Anagnostopoulos A, Aleman A, Ayers G, et al. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer. 2004;100(12):2607–2612.
  • Benson DM, Jr., Elder PJ, Lin TS, et al. High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma. Leuk Res. 2007;31(8):1069–1075.
  • Devarakonda S, Efebera Y, Sharma N. Role of stem cell transplantation in multiple myeloma. Cancers (Basel). 2021;13(4):863.
  • Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the intergroupe francophone du myélome 9502 randomized trial. Blood. 2002;99(3):731–735.
  • Annamaria Brioli M, Felix V H, Mügge L-O, et al. Full dose or reduced dose melphalan for autologous stem cell transplantation in multiple myeloma: a single center analysis on 187 consecutive patients. Blood. 2018;132(Supplement 1):4625–4625. MD MD MDMDPhD MD MD MD
  • Srour SA, Milton DR, Bashir Q, et al. Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Haematologica. 2021;106(12):3211–3214.
  • Auner HW, Iacobelli S, Sbianchi G, et al. Melphalan 140 mg/m(2) or 200 mg/m(2) for autologous transplantation in myeloma: results from the collaboration to collect autologous transplant outcomes in lymphoma and myeloma (CALM) study. A report by the EBMT chronic malignancies working party. Haematologica. 2018;103(3):514–521.
  • Holstein SA, Jung SH, Richardson PG, et al. Updated analysis of CALGB (alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017;4(9):e431–e442.
  • Richardson PG, Jacobus SJ, Weller EA, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387(2):132–147.
  • Straka C, Schaefer-Eckart K, Hertenstein B, et al. Long-term outcome of a prospective randomized trial comparing continuous lenalidomide/dexamethasone with lenalidomide/dexamethasone induction, MEL140 with autologous blood stem cell transplantation and single agent lenalidomide maintenance in patients of age 60-75 years with newly diagnosed myeloma. Blood. 2022;140(Supplement 1):287–288.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.